Quantum BioPharma Submits FDA Application for Lucid-21-302
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy QNTM?
Quantum BioPharma announced that it has formally submitted an investigational new drug application to the FDA for Lucid-21-302, its new drug candidate for the treatment of multiple sclerosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum BioPharma Submits IND Application for Lucid-MS
- IND Submission: Quantum BioPharma has formally submitted an Investigational New Drug (IND) application for Lucid-21-302 (Lucid-MS) to the FDA, marking a significant advancement in the treatment of multiple sclerosis (MS) and is expected to drive the company's strategic growth in the global neurological market.
- Clinical Trial Plans: The IND submission supports the planned Phase 2 clinical trial aimed at evaluating the efficacy, safety, and tolerability of Lucid-MS, building on favorable safety data from Phase 1 trials, thus laying a strong foundation for further development.
- Market Opportunity: With approximately 2.8 million people affected by multiple sclerosis globally, the MS therapeutic market is projected to exceed $38 billion by 2030, positioning Quantum BioPharma's innovative approach to directly target demyelination to meet unmet patient needs and capture significant market share.
- Strategic Investment and Growth: The CEO emphasized that the IND submission marks a crucial milestone in advancing Lucid-MS into clinical development, and by integrating its consumer health product UNBUZZD™, Quantum BioPharma aims to create shareholder value through disciplined investment in high-potential therapeutic programs.
See More
Quantum BioPharma Partners with Allucent for Phase 2 MS Trial
- Stock Surge: Quantum BioPharma (QNTM) shares jumped 15% in pre-market trading on Monday, reflecting strong market confidence in the company's future following its binding agreement with Allucent, indicating heightened investor optimism.
- Clinical Trial Initiative: Under the agreement, Allucent will support Quantum BioPharma's planned Phase 2 trial of the Lucid-MS therapy, set to begin in Q2 2026, aimed at evaluating the drug's safety, efficacy, and tolerability, showcasing the company's proactive approach in the multiple sclerosis treatment landscape.
- Innovative Therapeutic Mechanism: Lucid-MS is designed to protect nerves by targeting demyelination, a key factor in multiple sclerosis progression, offering a differentiated therapeutic approach compared to existing treatments that primarily focus on immune modulation, potentially attracting more patient interest.
- Significant Market Potential: With approximately 2.8 million people suffering from multiple sclerosis globally, Quantum BioPharma's innovative mechanism could carve out a niche in a competitive market, further driving the company's growth and development in the biopharmaceutical sector.
See More
Quantum BioPharma Announces Stock Option Grant
- Stock Option Grant: Quantum BioPharma has granted 35,000 stock options to certain employees and consultants, with an exercise price of CA$6.50 and a five-year term, aimed at incentivizing staff and enhancing talent retention within the company.
- Holding Restrictions: All stock options and the underlying common shares are subject to a statutory hold period of four months and one day post-issuance, which helps stabilize the shareholder structure and prevent short-term speculative trading.
- Innovative Drug Development: Quantum BioPharma, through its wholly-owned subsidiary Lucid Psycheceuticals, focuses on developing its lead compound Lucid-MS, which has shown potential to prevent and reverse myelin degradation in preclinical models, marking significant progress in treating multiple sclerosis.
- Future Revenue Expectations: The agreement with Unbuzzd includes a 7% royalty on sales until total payments reach $250 million, after which the royalty drops to 3%, providing the company with a long-term revenue stream to support ongoing R&D investments.
See More
QUANTUM BIOPHARMA ISSUES COMPANY UPDATE
Corporate Update: Quantum Biopharma has provided a corporate update detailing recent developments and strategic initiatives.
Financial Performance: The company highlighted its financial performance, including revenue growth and investment in research and development.
Product Pipeline: An overview of the current product pipeline was presented, showcasing advancements in various therapeutic areas.
Future Outlook: Quantum Biopharma discussed its future outlook, emphasizing plans for expansion and potential market opportunities.
See More
Quantum BioPharma Reports 2025 Financial Highlights and Drug Developments
- Strong Financial Position: As of December 31, 2025, Quantum BioPharma reported cash and fair market value of digital assets totaling $11.3 million, with management confident that this capital will sustain operations through January 2028, indicating a significant improvement in capital market access.
- Reduced R&D Expenses: External research and development fees decreased to $2.8 million in 2025 from $6.1 million in 2024, a reduction of approximately 54%, primarily due to the completion of Phase 1 clinical trials and R&D tax credits from the Australian government, showcasing effective cost management.
- Advancement of Lucid-MS: The oral toxicity studies for the multiple sclerosis drug candidate Lucid-21-302 have been completed, showing no toxicity or significant side effects, which sets the stage for the upcoming Phase 2 clinical trial and offers a potentially easier administration route for patients.
- unbuzzd Product Approval: Quantum's natural health product Qlarity has received a product license from Health Canada for sale in Canada, while unbuzzd is preparing for an IPO and aims to raise $5 million through a Regulation D 506(c) offering to support growth and distribution.
See More
Quantum BioPharma Revises Debenture Terms Amid Market Price Drop
- Debenture Terms Adjustment: In response to a decrease in the market price of its Class B subordinate voting shares, Quantum BioPharma has revised the conversion price of its Debenture Units to $3.00 per share, reflecting the company's agility in navigating market fluctuations.
- Warrant Price Reduction: The exercise price for the Warrants has been lowered to $3.75 per share, aimed at increasing investor participation and thereby enhancing the company's financing capabilities and market confidence.
- Debt Settlement Completion: The company will complete the debt settlement at the new conversion price, a move that not only alleviates financial burdens but also potentially improves cash flow, thereby enhancing operational flexibility for future growth.
- Tax Loss Carryforward: Quantum BioPharma retains approximately C$130 million in tax loss carryforwards, providing opportunities for tax relief against future profits, which further strengthens the company's financial health and investment appeal.
See More
Quantum BioPharma Submits IND Application for Lucid-MS
- IND Submission: Quantum BioPharma has formally submitted an Investigational New Drug (IND) application for Lucid-21-302 (Lucid-MS) to the FDA, marking a significant advancement in the treatment of multiple sclerosis (MS) and is expected to drive the company's strategic growth in the global neurological market.
- Clinical Trial Plans: The IND submission supports the planned Phase 2 clinical trial aimed at evaluating the efficacy, safety, and tolerability of Lucid-MS, building on favorable safety data from Phase 1 trials, thus laying a strong foundation for further development.
- Market Opportunity: With approximately 2.8 million people affected by multiple sclerosis globally, the MS therapeutic market is projected to exceed $38 billion by 2030, positioning Quantum BioPharma's innovative approach to directly target demyelination to meet unmet patient needs and capture significant market share.
- Strategic Investment and Growth: The CEO emphasized that the IND submission marks a crucial milestone in advancing Lucid-MS into clinical development, and by integrating its consumer health product UNBUZZD™, Quantum BioPharma aims to create shareholder value through disciplined investment in high-potential therapeutic programs.
See More
Quantum BioPharma Partners with Allucent for Phase 2 MS Trial
- Stock Surge: Quantum BioPharma (QNTM) shares jumped 15% in pre-market trading on Monday, reflecting strong market confidence in the company's future following its binding agreement with Allucent, indicating heightened investor optimism.
- Clinical Trial Initiative: Under the agreement, Allucent will support Quantum BioPharma's planned Phase 2 trial of the Lucid-MS therapy, set to begin in Q2 2026, aimed at evaluating the drug's safety, efficacy, and tolerability, showcasing the company's proactive approach in the multiple sclerosis treatment landscape.
- Innovative Therapeutic Mechanism: Lucid-MS is designed to protect nerves by targeting demyelination, a key factor in multiple sclerosis progression, offering a differentiated therapeutic approach compared to existing treatments that primarily focus on immune modulation, potentially attracting more patient interest.
- Significant Market Potential: With approximately 2.8 million people suffering from multiple sclerosis globally, Quantum BioPharma's innovative mechanism could carve out a niche in a competitive market, further driving the company's growth and development in the biopharmaceutical sector.
See More
Quantum BioPharma Announces Stock Option Grant
- Stock Option Grant: Quantum BioPharma has granted 35,000 stock options to certain employees and consultants, with an exercise price of CA$6.50 and a five-year term, aimed at incentivizing staff and enhancing talent retention within the company.
- Holding Restrictions: All stock options and the underlying common shares are subject to a statutory hold period of four months and one day post-issuance, which helps stabilize the shareholder structure and prevent short-term speculative trading.
- Innovative Drug Development: Quantum BioPharma, through its wholly-owned subsidiary Lucid Psycheceuticals, focuses on developing its lead compound Lucid-MS, which has shown potential to prevent and reverse myelin degradation in preclinical models, marking significant progress in treating multiple sclerosis.
- Future Revenue Expectations: The agreement with Unbuzzd includes a 7% royalty on sales until total payments reach $250 million, after which the royalty drops to 3%, providing the company with a long-term revenue stream to support ongoing R&D investments.
See More
QUANTUM BIOPHARMA ISSUES COMPANY UPDATE
Corporate Update: Quantum Biopharma has provided a corporate update detailing recent developments and strategic initiatives.
Financial Performance: The company highlighted its financial performance, including revenue growth and investment in research and development.
Product Pipeline: An overview of the current product pipeline was presented, showcasing advancements in various therapeutic areas.
Future Outlook: Quantum Biopharma discussed its future outlook, emphasizing plans for expansion and potential market opportunities.
See More
Quantum BioPharma Reports 2025 Financial Highlights and Drug Developments
- Strong Financial Position: As of December 31, 2025, Quantum BioPharma reported cash and fair market value of digital assets totaling $11.3 million, with management confident that this capital will sustain operations through January 2028, indicating a significant improvement in capital market access.
- Reduced R&D Expenses: External research and development fees decreased to $2.8 million in 2025 from $6.1 million in 2024, a reduction of approximately 54%, primarily due to the completion of Phase 1 clinical trials and R&D tax credits from the Australian government, showcasing effective cost management.
- Advancement of Lucid-MS: The oral toxicity studies for the multiple sclerosis drug candidate Lucid-21-302 have been completed, showing no toxicity or significant side effects, which sets the stage for the upcoming Phase 2 clinical trial and offers a potentially easier administration route for patients.
- unbuzzd Product Approval: Quantum's natural health product Qlarity has received a product license from Health Canada for sale in Canada, while unbuzzd is preparing for an IPO and aims to raise $5 million through a Regulation D 506(c) offering to support growth and distribution.
See More
Quantum BioPharma Revises Debenture Terms Amid Market Price Drop
- Debenture Terms Adjustment: In response to a decrease in the market price of its Class B subordinate voting shares, Quantum BioPharma has revised the conversion price of its Debenture Units to $3.00 per share, reflecting the company's agility in navigating market fluctuations.
- Warrant Price Reduction: The exercise price for the Warrants has been lowered to $3.75 per share, aimed at increasing investor participation and thereby enhancing the company's financing capabilities and market confidence.
- Debt Settlement Completion: The company will complete the debt settlement at the new conversion price, a move that not only alleviates financial burdens but also potentially improves cash flow, thereby enhancing operational flexibility for future growth.
- Tax Loss Carryforward: Quantum BioPharma retains approximately C$130 million in tax loss carryforwards, providing opportunities for tax relief against future profits, which further strengthens the company's financial health and investment appeal.
See More
